Following on from earlier acquisitions and investments on both sides of the Atlantic, Sterling Pharma Solutions has commenced a $2.1 million expansion project to increase chemical and analytical capabilities at its facility in Cary, North Carolina. The work should be completed by the end of 2022 and will create up to 20 new jobs. This will include five new laboratories: two for R&D, one for scaling up chemical synthesis and others for QC and analytical services.

Chinese CDMO WuXi STA is to build a new pharmaceutical clinical and commercial manufacturing complex on a 78-hectare campus in Middletown, Delaware. This has been supported by the Delaware Prosperity Partnership, other state departments and local government bodies, and received grants from the Delaware Strategic Fund.

Small molecule CDMO Cambrex is spending $50 million to expand its mid- and large-scale API manufacturing capacity in Charles City, Iowa. This is the sixth major investment at the site in the past eight years and follows on from a recent, smaller expansion at the site in Karlskroga, Sweden.

Small molecule CDMO Cambrex is to spend $3.6 million to increase flexible drug substance manufacturing capacity by 6 m³ (25%) at Karlskoga, Sweden, in response to growing demand for commercial-scale API manufacturing. Engineering work has already commenced and should be completed by November.